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BACKGROUND
Evidence is urgently needed to support treatment decisions for children with mul-
tisystem inflammatory syndrome (MIS-C) associated with severe acute respiratory 
syndrome coronavirus 2.
METHODS
We performed an international observational cohort study of clinical and outcome 
data regarding suspected MIS-C that had been uploaded by physicians onto a Web-
based database. We used inverse-probability weighting and generalized linear 
models to evaluate intravenous immune globulin (IVIG) as a reference, as compared 
with IVIG plus glucocorticoids and glucocorticoids alone. There were two primary 
outcomes: the first was a composite of inotropic support or mechanical ventilation 
by day 2 or later or death; the second was a reduction in disease severity on an 
ordinal scale by day 2. Secondary outcomes included treatment escalation and the 
time until a reduction in organ failure and inflammation.
RESULTS
Data were available regarding the course of treatment for 614 children from 32 
countries from June 2020 through February 2021; 490 met the World Health Or-
ganization criteria for MIS-C. Of the 614 children with suspected MIS-C, 246 re-
ceived primary treatment with IVIG alone, 208 with IVIG plus glucocorticoids, and 
99 with glucocorticoids alone; 22 children received other treatment combinations, 
including biologic agents, and 39 received no immunomodulatory therapy. Receipt 
of inotropic or ventilatory support or death occurred in 56 patients who received 
IVIG plus glucocorticoids (adjusted odds ratio for the comparison with IVIG alone, 
0.77; 95% confidence interval [CI], 0.33 to 1.82) and in 17 patients who received 
glucocorticoids alone (adjusted odds ratio, 0.54; 95% CI, 0.22 to 1.33). The adjusted 
odds ratios for a reduction in disease severity were similar in the two groups, as 
compared with IVIG alone (0.90 for IVIG plus glucocorticoids and 0.93 for gluco-
corticoids alone). The time until a reduction in disease severity was similar in the 
three groups.
CONCLUSIONS
We found no evidence that recovery from MIS-C differed after primary treatment with 
IVIG alone, IVIG plus glucocorticoids, or glucocorticoids alone, although significant 
differences may emerge as more data accrue. (Funded by the European Union’s 
Horizon 2020 Program and others; BATS ISRCTN number, ISRCTN69546370.)
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In April 2020, practitioners first not-ed a temporal association between infection with severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2)1-4 and multisystem inflam-
matory syndrome in children (MIS-C) as a rare but 
serious complication.5-8 Since that time, MIS-C 
has been reported to occur 2 to 6 weeks after 
SARS-CoV-2 infection and is characterized by 
persistent fever and nonspecific symptoms that 
include abdominal pain, vomiting, headache, and 
fatigue. Conjunctival injection (hyperemia) and 
rash resembling Kawasaki’s disease have occurred 
in a high percentage of children with this condi-
tion.4,6,9-11 Severely affected children have been 
reported with multiorgan failure and shock that 
requires inotropic support. Laboratory studies have 
shown intense inflammation with elevated lev-
els of C-reactive protein, ferritin, troponin, and 
N-terminal pro–B-type natriuretic peptide and 
reduced levels of hemoglobin, platelets, and lym-
phocytes.
Faced with a new disease with no proven 
therapy, pediatricians have treated patients using 
their “best guess” as to what might be beneficial. 
On the basis of the resemblance of MIS-C to 
Kawasaki’s disease,2,4,9,11 macrophage activation 
syndrome,12 and staphylococcal toxic shock syn-
drome,13,14 practitioners have preferentially cho-
sen immunomodulatory agents that have shown 
benefit in these diseases, with such drugs often 
used in combination or sequentially when initial 
treatments have failed.15-17
Since coronary-artery aneurysm is an impor-
tant overlapping feature of both MIS-C and Ka-
wasaki’s disease, intravenous immune globulin 
(IVIG), the proven treatment for Kawasaki’s dis-
ease,18 has been widely adopted as an initial 
therapy, and withholding IVIG is considered un-
acceptable by some clinicians. However, some 
children with MIS-C recover with supportive treat-
ment alone,3,15 so aggressive attempts to suppress 
the inflammatory response may not necessarily 
translate into clinical benefit.
Randomized trials are needed to establish the 
most effective treatment of MIS-C. However, giv-
en the rapid emergence of MIS-C during the coro-
navirus disease 2019 (Covid-19) pandemic — and 
concern that it may lead to death, multiorgan 
failure, or long-term cardiac damage — practi-
tioners have adopted the use of a range of un-
proven immunomodulators, which are now being 
recommended in local and national treatment 
guidelines.19,20 We performed the Best Available 
Treatment Study (BATS) to provide evidence for 
recommendations regarding the treatment of 
MIS-C by collecting and analyzing outcomes of 
the treatments chosen by individual pediatricians 
responsible for patient care.
Me thods
Study Design
We invited pediatricians worldwide to join our 
study by uploading data from their patients with 
suspected MIS-C onto a Web-based Research 
Electronic Data Capture database.21 Since the ac-
curacy of current MIS-C definitions is unknown 
and emerging experience suggests a wide spec-
trum of inflammatory illnesses after SARS-CoV-2 
infection,22,23 our study invited pediatricians to 
enroll not only children who met the published 
criteria for MIS-C24-26 but also those with any sus-
pected inflammatory illness after SARS-CoV-2 
infection. We collected deidentified longitudinal 
data regarding presenting features, demographic 
characteristics, laboratory findings, immuno-
modulatory treatments (IVIG, glucocorticoids, or 
biologic agents), and supportive therapies. Treat-
ments and daily data were collected according to 
the calendar day. We also recorded the duration 
of hospital admission, organ support required, 
and health status at the time of discharge. De-
tails regarding the study methods are provided 
in the Supplementary Appendix, available with the 
full text of this article at NEJM.org.
Comparison of Treatments
Three primary treatment groups were large 
enough to be considered for comparison: IVIG 
alone, IVIG plus glucocorticoids, and glucocorti-
coids alone. We chose IVIG alone as the refer-
ence treatment since it is the accepted treatment 
for Kawasaki’s disease and has been widely ad-
opted in the treatment of MIS-C. Thus, we com-
pared IVIG plus glucocorticoids and glucocorti-
coids alone with IVIG.
The first calendar day of each of the three 
treatments was defined as day 0, and the subse-
quent treatment and outcomes were defined rela-
tive to this initiation. Additional immunomod-
ulators that were administered on the same 
calendar day as the primary treatment were de-
fined as coprimary treatments, whereas immuno-
modulators that were administered on subse-
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quent days were considered to be secondary 
treatments.
Primary and Secondary Outcomes
There were two primary outcomes. The first was 
a composite of inotropic support or mechanical 
ventilation (invasive or noninvasive) by day 2 or 
later or death. The second was a reduction in dis-
ease severity on a seven-point ordinal scale be-
tween day 0 and day 2; the levels of disease se-
verity from worst to least were as follows: receipt 
of mechanical ventilation and inotropic support, 
receipt of mechanical ventilation alone, receipt of 
inotropic support alone, receipt of oxygen alone, 
no supportive therapy with a C-reactive protein 
level of 50 mg per liter or more, no supportive 
therapy with a C-reactive protein level of less 
than 50 mg per liter, and hospital discharge.
Key secondary outcomes were temporal dy-
namics of blood markers of inflammation and 
organ damage; an escalation in the administra-
tion of immunomodulators, which was defined 
as the addition of a separate immunomodulator 
or (if the initial treatment included glucocorti-
coids) an incremental increase of 5 mg per kilo-
gram of body weight or its equivalent in the 
daily dose of prednisolone; the time until a re-
duction of 1 point in disease severity on the or-
dinal scale; left ventricular dysfunction on echo-
cardiography; coronary-artery aneurysm after 
treatment (coronary-artery z score of ≥2.5 or 
documented aneurysm)27; any increase in cardio-
respiratory supportive therapy after day 0; and 
other therapeutic complications or death.
For the primary outcomes, we performed a 
subgroup analysis that included only the pa-
tients who met the World Health Organization 
(WHO) criteria for MIS-C26 and a sensitivity analy-
sis in which we defined the primary treatments 
as those received during the first two calendar 
days of immunomodulatory treatment.
Oversight
The study was designed by the study team at 
Imperial College London. Data regarding indi-
vidual patients were collected by local investiga-
tors. The statistical analysis plan was developed 
by the statistical group, who also performed the 
analyses. An international advisory board oversaw 
the progress of the study and the publication 
strategy. (Details regarding members of the study 
team, the investigator consortium, and interna-
tional advisory board are provided in the Supple-
mentary Appendix.)
The study was approved by the United King-
dom research ethics committee. Participating cen-
ters obtained ethical approval according to the 
requirements in each country. The initial draft 
of the manuscript was written by the last author 
and was developed by all the authors, who con-
stitute the writing group. The last author and 
members of the data-management and analysis 
groups had access to all the data and vouch for 
the completeness and accuracy of the data and 
for the fidelity of the study to the protocol and 
the statistical analysis plan.
Statistical Analysis
We used weighted logistic-regression methods to 
analyze dichotomous outcomes and performed 
time-to-event analyses using weighted Cox re-
gression methods, with weights determined by 
inverse probability according to covariate-balanc-
ing propensity scores to account for baseline 
differences among the three major treatment 
groups (IVIG alone, IVIG plus glucocorticoids, 
and glucocorticoids alone). These analyses in-
cluded the same covariates as were used for the 
propensity scores to produce doubly robust esti-
mates. The average treatment effect was estimat-
ed except as described otherwise. We reported 
outcomes as odds ratios or average hazard ratios 
with 95% confidence intervals, using IVIG alone 
as the reference category. (Details are provided 
in the Methods section in the Supplementary Ap-
pendix and in the statistical analysis plan in the 
protocol.)
Inflammatory markers were plotted as per-
centages of each patient’s peak value. Weighted 
generalized additive models were fitted to pro-
duce smoothed curves with confidence intervals. 
Weights were produced as outlined above; how-
ever, in comparing the patients who were treated 
with immunomodulatory drugs with those who 
did not receive such treatment, we estimated the 
average treatment effect in the untreated group 




From June 20, 2020, to February 24, 2021, prac-
titioners at 81 hospitals in 34 countries uploaded 
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data for 651 patients with suspected MIS-C to 
the study database (Figs. S1, S2, and S3 in the 
Supplementary Appendix). Data for 37 patients 
were excluded owing to incomplete information 
or duplicate entries. Of the remaining 614 pa-
tients, 246 received primary treatment with IVIG 
alone, 208 with IVIG plus glucocorticoids, and 
99 with glucocorticoids alone; another 22 pa-
A Primary Therapy Groups
B Treatments during First 5 Days of Hospitalization
614 Met inclusion criteria
651 Patients were enrolled
37 Were excluded
18 Were missing discharge date and daily data
9 Did not have edited treatment form
5 Were missing admission date
2 Had incomplete data cutoff
3 Had other reason
246 Were treated with IVIG
alone
192 Met WHO criteria for
MIS-C
1 Met WHO criteria for
MIS-C plus criteria 
for bacteremia or TSS
43 Were missing 1
WHO criterion for
MIS-C
10 Were missing >1
WHO criteria for
MIS-C
99 Were treated with
glucocorticoids alone
78 Met WHO criteria for
MIS-C
3 Met WHO criteria for
MIS-C plus criteria 
for bacteremia or TSS
17 Were missing 1
WHO criterion for
MIS-C
1 Was missing >1
WHO criteria for
MIS-C
208 Were treated with IVIG
plus glucocorticoids
186 Met WHO criteria for
MIS-C
1 Met WHO criteria for
MIS-C plus criteria  
for bacteremia or TSS
15 Were missing 1
WHO criterion for
MIS-C
6 Were missing >1
WHO criteria for
MIS-C
22 Received other immuno-
modulatory treatment
16 Met WHO criteria for
MIS-C
5 Were missing 1
WHO criterion for
MIS-C
1 Was missing >1
WHO criteria for
MIS-C
39 Received no immuno-
modulatory treatment
18 Met WHO criteria for
MIS-C
2 Met WHO criteria for
MIS-C plus criteria 
for bacteremia or TSS
12 Were missing 1
WHO criterion for
MIS-C
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tients received other immunomodulators, and 39 
received no immunomodulatory therapy (Fig. 1A). 
In the three primary treatment groups, 136 of 
552 patients (25%) had received additional im-
munomodulators by day 2, and 238 patients (43%) 
received secondary agents at any time. The com-
plex changes in treatments are shown in Fig-
ure 1B.
Clinical and Laboratory Measures
Clinical and laboratory findings were similar 
among the treatment groups (Table 1 and Table 
S2). However, troponin levels and the percentage 
of patients who received inotropes on day 0 were 
higher in the group that received IVIG plus glu-
cocorticoids (Figs. S4, S5, and S6). Of the 614 
patients, 490 (80%) met the WHO criteria for 
MIS-C (Table S3). The most common criterion 
that was missing among the patients who did not 
meet the WHO criteria was evidence of SARS-
CoV-2 exposure (Fig. S7). SARS-CoV-2 antibody 
measurements were not tested in 14% of the 
patients, and results were negative in 14%. Bac-
teria were cultured in blood samples obtained 
from 6 patients. The percentage of patients who 
met the American Heart Association (AHA) defi-
nition for Kawasaki’s disease18 was 37% in the 
overall population and 39% among those who 
met the WHO criteria for MIS-C (Table S4 and 
Fig. S8).
Primary Outcomes
A total of 50 of 553 patients (9%) received im-
munomodulators before transfer to the report-
ing hospital and were excluded from the weight-
ed analyses. The receipt of inotropic support or 
mechanical ventilation on day 2 or later or death 
(the first primary outcome) occurred in 56 pa-
tients who received initial treatment with IVIG 
plus glucocorticoids (adjusted odds ratio for the 
comparison with IVIG alone, 0.77; 95% confi-
dence interval [CI], 0.33 to 1.82) and in 17 patients 
who received glucocorticoids alone (adjusted odds 
ratio, 0.54; 95% CI, 0.22 to 1.33) (Fig. 2). Unad-
justed values are shown in Table S5.
In a subgroup analysis that included only the 
patients who met the WHO criteria for MIS-C, a 
first-primary-outcome event occurred in 40 pa-
tients who received initial treatment with IVIG 
plus glucocorticoids (adjusted odds ratio for the 
comparison with IVIG alone, 0.95; 95% CI, 0.37 
to 2.45) and in 12 patients who received initial 
treatment with glucocorticoids alone (adjusted 
odds ratio, 0.30; 95% CI, 0.10 to 0.85). The results 
for the individual components of the composite 
outcome are shown in Figure 2 and Table S5.
A reduction in the score for disease severity 
on the ordinal scale by day 2 (the second pri-
mary outcome) occurred in 54 patients who re-
ceived IVIG plus glucocorticoids (adjusted odds 
ratio for the comparison with IVIG alone, 0.90; 
95% CI, 0.48 to 1.69) and in 20 patients who 
received glucocorticoids alone (adjusted odds ra-
tio, 0.93; 95% CI, 0.43 to 2.04). When WHO crite-
ria for MIS-C were considered in a subgroup 
analysis, a second-primary-outcome event occurred 
in 52 patients who received IVIG plus glucocor-
ticoids (adjusted odds ratio for the comparison 
with IVIG alone, 1.09; 95% CI, 0.53 to 2.23) and 
in 16 patients who received glucocorticoids alone 
(adjusted odds ratio, 1.95; 95% CI, 0.83 to 4.60).
Figure 1 (facing page). Study Enrollment and Treatments 
after Hospital Admission.
Panel A shows an overview of the total number of chil‑
dren with suspected multisystem inflammatory syn‑
drome (MIS‑C) associated with severe acute respirato‑
ry syndrome coronavirus 2 who were enrolled in the 
study, according to treatment received. Patients who 
met the inclusion criteria were categorized according 
to enrollment in the three main treatment groups — 
intravenous immune globulin (IVIG) alone, IVIG plus 
glucocorticoids, and glucocorticoids alone — along 
with other immunomodulatory treatments (including 
anti–tumor necrosis factor, anti–interleukin‑1, and 
anti–interleukin‑6). Patients were further categorized 
according to whether they met the clinical criteria of 
the World Health Organization (WHO) for MIS‑C.  
TSS denotes toxic shock syndrome.
Panel B shows a Sankey diagram of treatments re‑
ceived by patients after hospital admission. Each verti‑
cal stack represents day 0 to 5 in the patient’s hospital 
admission. The arrows (gray bands) represent the 
movement of patients between treatment groups on 
subsequent days; the width of the arrows is propor‑
tional to the flow rate between days. Patients in the 
group that received glucocorticoids alone could have 
received either intravenous or oral formulations, and 
the continuation of glucocorticoid treatments on sub‑
sequent days at the same or lower dose did not con‑
stitute additional treatment. Other treatments — 
which included one or more other immunomodulatory 
therapies given alone or in combination with glucocor‑
ticoids, IVIG, or both — were anti–tumor necrosis fac‑
tor, anti–interleukin‑1, anti–interleukin‑6, extracorpo‑
real cytokine adsorber (CytoSorb), granulocyte 
colony‑stimulating factor, colchicine, mesenchymal 
stem cells, and convalescent plasma.
n engl j med nejm.org 6
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The results for the two primary outcomes 
showed an acceptable degree of balance with 
respect to the covariates (Fig. S9). Analyses that 
were performed with the use of standardized 
weights did not change the interpretation of the 
primary outcomes.
Secondary Outcomes
Escalation of immunomodulatory treatment was 
less common among the patients who received 
IVIG plus glucocorticoids than among those who 
received IVIG alone (odds ratio, 0.18; 95% CI, 0.10 
to 0.33). The comparison was inconclusive between 
the patients who received glucocorticoids alone 
and those who received IVIG alone (odds ratio, 
1.31; 95% CI, 0.64 to 2.68) (Table S5; Table S1 
shows additional details regarding treatment es-
calation according to group). No clear between-
group differences were seen in blood markers, 
inotropic support, or mechanical ventilation be-
tween patients who had an escalation to other 
treatments by day 2 and those who continued to 
receive the initial treatment (Figs. S5 and S6B).
Left ventricular dysfunction was reported in 
12% of the 538 patients who had undergone echo-
cardiography starting on day 2, with no substantial 
differences among the treatment groups. Coro-
nary-artery aneurysm was present on the latest 
echocardiogram at 2 days after the initiation of 
treatment or later in 6% of the 326 patients for 
whom data were available. The low numbers of 
coronary-artery aneurysms that were detected 
preclude statistical comparisons among the treat-
ment groups, although among the patients with 
data, the incidence of coronary-artery aneurysm 
was not greater among those who did not receive 
any IVIG as part of primary treatment than 
among those who did receive IVIG (Table S6). 
Death was reported in 3 of 238 patients (1%) who 
received IVIG alone, in 5 of 192 patients (3%) who 
received IVIG plus glucocorticoids, and in 4 of 
91 patients (4%) who received glucocorticoids 
alone; status with respect to death was not re-
ported for 32 patients (Table S5).
In the analysis of the time until an improve-
ment in disease severity on the ordinal scale, the 
average hazard ratio for the comparison with 
IVIG alone was 0.89 (95% CI, 0.67 to 1.19) for 
IVIG plus glucocorticoids and 1.03 (95% CI, 0.72 
to 1.46) for glucocorticoids alone (Fig. S9 and 
Table S5C).
Drug complications were reported by clini-
cians in 16 of 411 patients (4%) who received 
glucocorticoids in any combination and in 9 of 
408 (2%) who received IVIG in any combination. 
Glucocorticoid-related complications were pre-
dominantly hypertension and hyperglycemia 
(Table S7).
Effect of Immunomodulation on Blood 
Markers
Levels of C-reactive protein decreased more rap-
idly in patients who received immunomodulators 
than in those who did not receive such treatment 
(Fig. 3A). Changes in levels of C-reactive protein, 
troponin, and ferritin followed a similar tempo-
ral decrease in the three groups (Fig. 3B), although 
there was some variation in the rate of decline, 
which was most obvious in the patients who did 
not change treatment before day 3 (Fig. 3C).
To investigate whether the inclusion of chil-
dren with Kawasaki’s disease in the present study 
might have influenced treatment responses, we 
explored changes in blood markers separately in 
children with a likely diagnosis of Kawasaki’s 
disease and in those without such a diagnosis. 
Since Kawasaki’s disease generally is more fre-
quent in children before the age of 6 years and 
MIS-C is generally reported in older children, we 
compared the patients who met the AHA criteria 
for Kawasaki’s disease and all those under the 
age of 6 years (whose illness may be described 
as Kawasaki’s disease–like) with the remaining 
patients with MIS-C. Among the children who 
received IVIG alone, the smoothed curves showed 
rates of decline in C-reactive protein levels among 
those younger than 6 years of age who met the 
AHA criteria for Kawasaki’s disease that were 
similar to the rates among the remaining chil-
dren. However, among the children who received 
glucocorticoids with or without IVIG, there was 
a more rapid decline in the C-reactive protein 
level in the group of children who did not meet 
the AHA criteria for Kawasaki’s disease or were 
over 6 years of age (Fig. S10).
Discussion
In a pragmatically defined international cohort 
of patients with suspected MIS-C, we found no 
evidence of substantial differences in the two 
primary outcomes among children who received 
the three most common treatments for this dis-
order (IVIG alone, IVIG plus glucocorticoids, and 
n engl j med nejm.org 8
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A Comparison of IVIG plus Glucocorticoids versus IVIG Alone
B Comparison of Glucocorticoids Alone versus IVIG Alone
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glucocorticoids alone). However, when we restrict-
ed the analyses to patients who met the WHO 
criteria for MIS-C, we found modest evidence of 
benefit with glucocorticoids alone over IVIG 
alone for both primary outcomes.
Analyses of secondary outcomes showed a 
lower frequency of escalation in immunomodu-
latory treatment (i.e., the addition of secondary 
agents) in patients receiving IVIG plus glucocor-
ticoids than in those receiving either IVIG alone 
or glucocorticoids alone. We did not find clear 
evidence for an association between initial treat-
ment with any of the three treatments and 
changes in organ failure, inflammation, or dis-
charge from the hospital. The frequency of cor-
onary-artery aneurysm was also similar in the 
three groups, but the percentage of patients with 
data regarding coronary-artery aneurysm was too 
low for firm conclusions to be made.
In a French national surveillance study involv-
ing patients with MIS-C,28 investigators found that 
patients who received IVIG plus glucocorticoids 
had a lower frequency of treatment escalation 
than those who received IVIG alone, along with 
a reduced need for hemodynamic support and a 
shorter stay in the intensive care unit. However, 
this study did not include a glucocorticoid-only 
group and had a smaller enrollment of patients 
than our study.
The high rates of escalation to additional treat-
ments in patients receiving single agents may be 
explained by a failure of the initial treatment or 
by the severity of illness, as well as by a greater 
readiness to escalate therapy when only one 
treatment was given. An increased percentage of 
patients who received IVIG plus glucocorticoids 
were also receiving inotropes at day 0. These 
patients had higher levels of troponin than those 
in the other two groups, which suggests that 
patients who were more severely ill may have re-
ceived IVIG plus glucocorticoids. However, patients 
who were receiving additional treatment by day 
2 did not receive more inotropic or ventilatory 
support or have higher troponin levels than those 
who did not undergo treatment escalation.
We measured levels of C-reactive protein and 
ferritin to explore how the different agents may 
have affected inflammation as surrogates for a 
determination of overall inflammation, and we 
measured troponin as a marker of cardiac injury. 
After adjustment for baseline differences in ill-
ness severity, the rate of reduction in the C-reac-
tive protein level appeared to be more rapid in 
patients who received immunomodulators.
Since the clinical features of MIS-C overlap with 
those of Kawasaki’s disease, a major dilemma in 
treatment decisions for MIS-C has been whether 
treatment regimens that do not include IVIG (the 
proven treatment for Kawasaki’s disease) may delay 
recovery and increase the risk of coronary-artery 
aneurysm. We found no evidence of delayed recov-
ery from organ failure in patients who received 
glucocorticoids alone as their initial treatment. 
When we restricted the analysis to patients who 
met the WHO criteria for MIS-C, we found a pos-
sible benefit for glucocorticoids alone in reducing 
the frequency of organ failure and a reduction in 
the score on the ordinal scale, although this com-
parison was confounded by the high percentage of 
patients with treatment escalation to IVIG plus 
glucocorticoids. The frequency of coronary-artery 
aneurysm across all three treatment groups was 
low (6%), so firm conclusions could not be drawn 
with respect to that complication.
We explored whether the inadvertent inclu-
sion of patients with Kawasaki’s disease in the 
MIS-C cohort may have prevented the detection 
of benefit from non-IVIG treatments. We found 
suggestive evidence that the rate of decline in 
the C-reactive protein level in response to immu-
nomodulators may have differed between younger 
children who met the AHA criteria for Kawasa-
ki’s disease and other children with suspected 
MIS-C. This finding supports our concern that 
the challenge of making a clinical distinction 
between these two diseases may increase the 
difficulty in identifying differences among the 
treatments for MIS-C.
Our study included patients who met the 
Figure 2 (facing page). Forest Plots for Primary,  
Secondary, and Subgroup Analyses.
Shown are outcomes for patients with suspected  
MIS‑C who received IVIG plus glucocorticoids (Panel A) 
or glucocorticoids alone (Panel B) as compared with 
those who received IVIG alone (reference group, indi‑
cated by an odds ratio or average hazard ratio of 1.00). 
Odds ratios are shown for all comparisons except 
time‑to‑event analyses, for which average hazard ratios 
were calculated. Values to the right of the dashed verti‑
cal line indicate the superiority of IVIG alone, except 
for the second primary outcome (a reduction in dis‑
ease severity on the ordinal scale by day 2, indicated  
by blue arrows), for which values to the left indicate 
the superiority of IVIG alone.
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Figure 3. Changes in Levels of C-Reactive Protein, Troponin, and Ferritin, According to Type of Treatment and Timing.
Each of three key markers of inflammation (C‑reactive protein, troponin, and ferritin) is plotted as a line and weighted by the covariate‑
balancing propensity score. The levels are shown as a percentage of each patient’s peak value. A generalized additive model was used  
to fit the curves. Panel A shows the fitted curves for the three measures in patients who received any immunomodulators, as compared 
with those who did not receive immunomodulators. Panel B shows the fitted curves for patients who received IVIG alone, IVIG plus glu‑
cocorticoids, and glucocorticoids alone as their primary treatment. Panel C shows the fitted curves for the three treatments combined 
in the patients whose primary treatment did not change between the day of admission (0) and day 3.
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WHO definition of MIS-C as well as patients 
lacking one or more criteria for this diagnosis. 
The current criteria are imperfect, since antibody 
testing is not always available and a history of 
exposure to SARS-CoV-2 lacks specificity be-
cause asymptomatic infection is common. Since 
MIS-C includes a broad spectrum of illnesses, 
until a diagnostic test is developed, clinicians 
will face difficult treatment decisions when they 
encounter a wider group of inflammatory dis-
eases that occur after SARS-CoV-2 infection than 
those identified by WHO criteria.
MIS-C has emerged as an important compli-
cation of SARS-CoV-2 infection among children 
in low- and middle-income countries.29,30 IVIG 
and biologic agents are costly and have limited 
availability in many countries, so evidence to 
support their use in preference to cheaper anti-
inflammatory agents such as glucocorticoids is 
needed. Since our study does not provide conclu-
sive evidence for either equivalence or superior-
ity of any of the three treatments that were 
evaluated, ongoing recruitment and analysis of a 
larger number of patients are needed to provide 
definitive evidence.
Our study has some limitations. Since our 
data did not come from randomized studies, a 
major concern is whether treatment selection 
was biased by the severity of illness. Our use of 
propensity-score weighting reduced bias. How-
ever, bias may also have been introduced by the 
fact that some patients received additional treat-
ments after their primary treatment. Higher 
rates of treatment escalation in single-agent 
groups may have masked differences in efficacy. 
In addition, the status with respect to aneurysm 
on day 2 and beyond was unavailable for 35% of 
the study patients, and we did not specifically 
collect follow-up data on coronary-artery aneu-
rysm. Thus, the current findings are insufficient 
to suggest equivalence of glucocorticoids with 
IVIG in preventing coronary-artery aneurysm.
Overall, we found no evidence of differences 
in outcomes between treatment with glucocorti-
coids or IVIG as single agents or between the 
single-agent and dual-agent primary treatments. 
The confidence intervals for inferences about 
treatment effect admit the possibility of actual 
benefit from one or more of the treatments rela-
tive to the others.
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